Astrid Marot1, Aïmen Belaid2, Hans Orlent3, Thomas Sersté4, Peter Michielsen5, Isabelle Colle6, Wim Laleman7, Chantal de Galocsy8, Hendrik Reynaert9, François D'Heygere10, Christophe Moreno11, Christopher Doerig1, Jean Henrion2, Pierre Deltenre12. 1. Division of Gastroenterology and Hepatology, centre hospitalier universitaire vaudois, University of Lausanne, rue du Bugnon, 44, 1011 Lausanne, Switzerland. 2. Department of Gastroenterology and Hepatology, hôpital de Jolimont, 7100 Haine-Saint-Paul, Belgium. 3. Department of Gastroenterology and Hepatology, AZ St Jan, 8000 Brugge, Belgium. 4. Department of Gastroenterology and Hepatology, CHU Saint-Pierre, 1000 Brussels, Belgium. 5. Department of Gastroenterology and Hepatology, UZ Antwerpen, 2650 Edegem, Belgium. 6. Department of Gastroenterology and Hepatology, Ghent University Hospital, 9000 Ghent, Belgium. 7. Department of Gastroenterology and Hepatology, KUL, 3000 Leuven, Belgium. 8. Department of Gastroenterology and Hepatology, hôpitaux Iris Sud Bracops, 1070 Brussels, Belgium. 9. Department of Gastroenterology and Hepatology, UZ Brussel, 1090 Brussels, Belgium. 10. Department of Gastroenterology and Hepatology, AZ Groeninge, 8510 Kortrijk, Belgium. 11. Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB hôpital Erasme, université Libre de Bruxelles, 1070 Brussels, Belgium. 12. Division of Gastroenterology and Hepatology, centre hospitalier universitaire vaudois, University of Lausanne, rue du Bugnon, 44, 1011 Lausanne, Switzerland; Department of Gastroenterology, Hepatopancreatology and Digestive Oncology, CUB hôpital Erasme, université Libre de Bruxelles, 1070 Brussels, Belgium. Electronic address: pierre.deltenre@chuv.ch.
Abstract
The epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections is continuously evolving. Updated data on dual HBV and HCV infection are still needed. AIMS: To assess the main characteristics of patients with HBV and HCV dual infection, to compare these with those of patients infected with either HBV or HCV and, among patients with dual infection, to assess fibrosis according to HCV replication. METHODS: Data of 23 patients with dual infection were compared to data from 92 age and sex-matched HBV or HCV monoinfected patients. RESULTS: Patients with dual infection were more often immigrants from Africa or Asia than HCV or HBV patients (52% vs. 20% and 22%, respectively, P=0.01). Intravenous drug use was the route of transmission in 22% of patients with dual infection, which was less frequent than in HCV patients (41%) but more frequent than in HBV patients (0%). Extensive fibrosis or cirrhosis was as frequent among dual-infected patients as among those with HCV or chronic hepatitis B infection (19% vs. 29% vs. 14%, respectively, P=0.4), even when fibrosis stage was reported considering the duration of infection. In dual-infected patients, the prevalence of extensive fibrosis or cirrhosis was similar in patients with and without detectable HCV RNA (18% vs. 20%). CONCLUSIONS: Patients with HBV and HCV dual infection were more often immigrants from Africa or Asia and had similar fibrosis stages than HCV or HBV monoinfected patients. In patients with dual infection, extensive fibrosis or cirrhosis was not associated with HCV replication.
The epidemiology of hepatitis B virus (HBV) and hepatitis C virus (HCV) infections is continuously evolving. Updated data on dual HBV and HCV infection are still needed. AIMS: To assess the main characteristics of patients with HBV and HCV dual infection, to compare these with those of patients infected with either HBV or HCV and, among patients with dual infection, to assess fibrosis according to HCV replication. METHODS: Data of 23 patients with dual infection were compared to data from 92 age and sex-matched HBV or HCV monoinfected patients. RESULTS:Patients with dual infection were more often immigrants from Africa or Asia than HCV or HBVpatients (52% vs. 20% and 22%, respectively, P=0.01). Intravenous drug use was the route of transmission in 22% of patients with dual infection, which was less frequent than in HCVpatients (41%) but more frequent than in HBVpatients (0%). Extensive fibrosis or cirrhosis was as frequent among dual-infected patients as among those with HCV or chronic hepatitis B infection (19% vs. 29% vs. 14%, respectively, P=0.4), even when fibrosis stage was reported considering the duration of infection. In dual-infected patients, the prevalence of extensive fibrosis or cirrhosis was similar in patients with and without detectable HCV RNA (18% vs. 20%). CONCLUSIONS:Patients with HBV and HCV dual infection were more often immigrants from Africa or Asia and had similar fibrosis stages than HCV or HBV monoinfected patients. In patients with dual infection, extensive fibrosis or cirrhosis was not associated with HCV replication.
Authors: Regiane M A Sampaio; Paola Eduarda F Dantas; Maria Inês C da Silva; Joseane R da Silva; Patrícia F Nunes; Amanda C Gomes; Luisa C Martins Journal: Viruses Date: 2022-04-21 Impact factor: 5.818